Serum proBDNF/BDNF and response to fluvoxamine in drug-nai¨ve first-episode major depressive disorder patients

Reiji Yoshimura, Taro Kishi, Hikaru Hori, Kiyokazu Atake, Asuka Katsuki, Wakako Nakano-Umene, Atsuko Ikenouchi-Sugita, Nakao Iwata, Jun Nakamura

研究成果: Article

16 引用 (Scopus)

抄録

Background: We investigated the association between serum proBDNF, a precursor of brain-derived neurotrophic factor (BDNF), and response to fluvoxamine in patients with major depressive disorder (MDD) using the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR): physically healthy and free of current alcohol or drug abuse, comorbid anxiety, or personality disorders.Methods: Fifty-one patients with MDD (M/F, 19:32; age, 38 ± 19 years) and 51 healthy controls (M/F, 22:29; age, 34 ± 17 years) were studied using DSM-IV-TR: physically healthy and free of current alcohol or drug abuse, comorbid anxiety, or personality disorders. Serum levels of proBDNF and MDNF were measured by sandwich enzyme-linked immunosorbent assay (ELISA). Results: Serum mature BDNF levels in the MDD patients were significantly lower than those in the healthy controls (t = 3.046, p = 0.0018). On the other hand, no difference was found in serum proBDNF between the MDD patients and the healthy controls (t = -0.979, p = 0.833). A trend of negative correlation was found between baseline serum BDNF and baseline scores of the 17 items of the Hamilton Rating Scale for Depression (HAMD17) (r = -0.183, p = 0.071). No correlation was however found between HAMD17 scores and proBDNF at baseline (r = 0.092, p = 0.421). Furthermore, no correlation was observed between baseline HAMD17 scores and baseline proBDNF/BDNF (r = -0.130, p = 0.190). No changes were observed in serum levels of proBDNF and BDNF during the treatment periods. Conclusions: These results suggest that there is no association between serum proBDNF/BDNF and fluvoxamine response in MDD patients at least within 4 weeks of the treatment.

元の言語English
記事番号19
ジャーナルAnnals of General Psychiatry
13
発行部数1
DOI
出版物ステータスPublished - 09-07-2014

Fingerprint

Fluvoxamine
Brain-Derived Neurotrophic Factor
Major Depressive Disorder
Serum
Pharmaceutical Preparations
Diagnostic and Statistical Manual of Mental Disorders
Personality Disorders
Anxiety Disorders
Alcoholism
Substance-Related Disorders
Enzyme-Linked Immunosorbent Assay
Depression
Therapeutics

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health

これを引用

Yoshimura, R., Kishi, T., Hori, H., Atake, K., Katsuki, A., Nakano-Umene, W., ... Nakamura, J. (2014). Serum proBDNF/BDNF and response to fluvoxamine in drug-nai¨ve first-episode major depressive disorder patients. Annals of General Psychiatry, 13(1), [19]. https://doi.org/10.1186/1744-859X-13-19
Yoshimura, Reiji ; Kishi, Taro ; Hori, Hikaru ; Atake, Kiyokazu ; Katsuki, Asuka ; Nakano-Umene, Wakako ; Ikenouchi-Sugita, Atsuko ; Iwata, Nakao ; Nakamura, Jun. / Serum proBDNF/BDNF and response to fluvoxamine in drug-nai¨ve first-episode major depressive disorder patients. :: Annals of General Psychiatry. 2014 ; 巻 13, 番号 1.
@article{ab8e0182a7e24b499973b99694d68b42,
title = "Serum proBDNF/BDNF and response to fluvoxamine in drug-nai¨ve first-episode major depressive disorder patients",
abstract = "Background: We investigated the association between serum proBDNF, a precursor of brain-derived neurotrophic factor (BDNF), and response to fluvoxamine in patients with major depressive disorder (MDD) using the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR): physically healthy and free of current alcohol or drug abuse, comorbid anxiety, or personality disorders.Methods: Fifty-one patients with MDD (M/F, 19:32; age, 38 ± 19 years) and 51 healthy controls (M/F, 22:29; age, 34 ± 17 years) were studied using DSM-IV-TR: physically healthy and free of current alcohol or drug abuse, comorbid anxiety, or personality disorders. Serum levels of proBDNF and MDNF were measured by sandwich enzyme-linked immunosorbent assay (ELISA). Results: Serum mature BDNF levels in the MDD patients were significantly lower than those in the healthy controls (t = 3.046, p = 0.0018). On the other hand, no difference was found in serum proBDNF between the MDD patients and the healthy controls (t = -0.979, p = 0.833). A trend of negative correlation was found between baseline serum BDNF and baseline scores of the 17 items of the Hamilton Rating Scale for Depression (HAMD17) (r = -0.183, p = 0.071). No correlation was however found between HAMD17 scores and proBDNF at baseline (r = 0.092, p = 0.421). Furthermore, no correlation was observed between baseline HAMD17 scores and baseline proBDNF/BDNF (r = -0.130, p = 0.190). No changes were observed in serum levels of proBDNF and BDNF during the treatment periods. Conclusions: These results suggest that there is no association between serum proBDNF/BDNF and fluvoxamine response in MDD patients at least within 4 weeks of the treatment.",
author = "Reiji Yoshimura and Taro Kishi and Hikaru Hori and Kiyokazu Atake and Asuka Katsuki and Wakako Nakano-Umene and Atsuko Ikenouchi-Sugita and Nakao Iwata and Jun Nakamura",
year = "2014",
month = "7",
day = "9",
doi = "10.1186/1744-859X-13-19",
language = "English",
volume = "13",
journal = "Annals of General Psychiatry",
issn = "1744-859X",
publisher = "BioMed Central",
number = "1",

}

Yoshimura, R, Kishi, T, Hori, H, Atake, K, Katsuki, A, Nakano-Umene, W, Ikenouchi-Sugita, A, Iwata, N & Nakamura, J 2014, 'Serum proBDNF/BDNF and response to fluvoxamine in drug-nai¨ve first-episode major depressive disorder patients', Annals of General Psychiatry, 巻. 13, 番号 1, 19. https://doi.org/10.1186/1744-859X-13-19

Serum proBDNF/BDNF and response to fluvoxamine in drug-nai¨ve first-episode major depressive disorder patients. / Yoshimura, Reiji; Kishi, Taro; Hori, Hikaru; Atake, Kiyokazu; Katsuki, Asuka; Nakano-Umene, Wakako; Ikenouchi-Sugita, Atsuko; Iwata, Nakao; Nakamura, Jun.

:: Annals of General Psychiatry, 巻 13, 番号 1, 19, 09.07.2014.

研究成果: Article

TY - JOUR

T1 - Serum proBDNF/BDNF and response to fluvoxamine in drug-nai¨ve first-episode major depressive disorder patients

AU - Yoshimura, Reiji

AU - Kishi, Taro

AU - Hori, Hikaru

AU - Atake, Kiyokazu

AU - Katsuki, Asuka

AU - Nakano-Umene, Wakako

AU - Ikenouchi-Sugita, Atsuko

AU - Iwata, Nakao

AU - Nakamura, Jun

PY - 2014/7/9

Y1 - 2014/7/9

N2 - Background: We investigated the association between serum proBDNF, a precursor of brain-derived neurotrophic factor (BDNF), and response to fluvoxamine in patients with major depressive disorder (MDD) using the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR): physically healthy and free of current alcohol or drug abuse, comorbid anxiety, or personality disorders.Methods: Fifty-one patients with MDD (M/F, 19:32; age, 38 ± 19 years) and 51 healthy controls (M/F, 22:29; age, 34 ± 17 years) were studied using DSM-IV-TR: physically healthy and free of current alcohol or drug abuse, comorbid anxiety, or personality disorders. Serum levels of proBDNF and MDNF were measured by sandwich enzyme-linked immunosorbent assay (ELISA). Results: Serum mature BDNF levels in the MDD patients were significantly lower than those in the healthy controls (t = 3.046, p = 0.0018). On the other hand, no difference was found in serum proBDNF between the MDD patients and the healthy controls (t = -0.979, p = 0.833). A trend of negative correlation was found between baseline serum BDNF and baseline scores of the 17 items of the Hamilton Rating Scale for Depression (HAMD17) (r = -0.183, p = 0.071). No correlation was however found between HAMD17 scores and proBDNF at baseline (r = 0.092, p = 0.421). Furthermore, no correlation was observed between baseline HAMD17 scores and baseline proBDNF/BDNF (r = -0.130, p = 0.190). No changes were observed in serum levels of proBDNF and BDNF during the treatment periods. Conclusions: These results suggest that there is no association between serum proBDNF/BDNF and fluvoxamine response in MDD patients at least within 4 weeks of the treatment.

AB - Background: We investigated the association between serum proBDNF, a precursor of brain-derived neurotrophic factor (BDNF), and response to fluvoxamine in patients with major depressive disorder (MDD) using the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR): physically healthy and free of current alcohol or drug abuse, comorbid anxiety, or personality disorders.Methods: Fifty-one patients with MDD (M/F, 19:32; age, 38 ± 19 years) and 51 healthy controls (M/F, 22:29; age, 34 ± 17 years) were studied using DSM-IV-TR: physically healthy and free of current alcohol or drug abuse, comorbid anxiety, or personality disorders. Serum levels of proBDNF and MDNF were measured by sandwich enzyme-linked immunosorbent assay (ELISA). Results: Serum mature BDNF levels in the MDD patients were significantly lower than those in the healthy controls (t = 3.046, p = 0.0018). On the other hand, no difference was found in serum proBDNF between the MDD patients and the healthy controls (t = -0.979, p = 0.833). A trend of negative correlation was found between baseline serum BDNF and baseline scores of the 17 items of the Hamilton Rating Scale for Depression (HAMD17) (r = -0.183, p = 0.071). No correlation was however found between HAMD17 scores and proBDNF at baseline (r = 0.092, p = 0.421). Furthermore, no correlation was observed between baseline HAMD17 scores and baseline proBDNF/BDNF (r = -0.130, p = 0.190). No changes were observed in serum levels of proBDNF and BDNF during the treatment periods. Conclusions: These results suggest that there is no association between serum proBDNF/BDNF and fluvoxamine response in MDD patients at least within 4 weeks of the treatment.

UR - http://www.scopus.com/inward/record.url?scp=84903868548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903868548&partnerID=8YFLogxK

U2 - 10.1186/1744-859X-13-19

DO - 10.1186/1744-859X-13-19

M3 - Article

AN - SCOPUS:84903868548

VL - 13

JO - Annals of General Psychiatry

JF - Annals of General Psychiatry

SN - 1744-859X

IS - 1

M1 - 19

ER -